Clinical Trials
68 trialsClinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy
University of Pittsburgh
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
Guangzhou Bio-gene Technology Co., Ltd
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
UNC Lineberger Comprehensive Cancer Center
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Juventas Cell Therapy Ltd.
B-ALL
Juventas Cell Therapy Ltd.
BIOSELECT
AHS Cancer Control Alberta
Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)
Dizal Pharmaceuticals
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
ImmunityBio, Inc.
Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas
VectivBio AG
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Fred Hutchinson Cancer Center
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Indiana University
Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
Zhujiang Hospital
CAR19T2
Zhujiang Hospital
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Indiana University
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
Children's Oncology Group
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
M.D. Anderson Cancer Center
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
University of Nebraska
Zandelisib + Tazemetostat in R/R Follicular Lymphoma
Massachusetts General Hospital
Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma
City of Hope Medical Center
STP-LYM-01
Technical University of Munich
Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies
Kunming Hope of Health Hospital
Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
Kunming Hope of Health Hospital
Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
Milton S. Hershey Medical Center
TACTIC-19
Triumvira Immunologics, Inc.
Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia
Roswell Park Cancer Institute
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
Celgene
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
Gilead Sciences
PLACARD
University College, London
Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas
Abramson Cancer Center at Penn Medicine
PLM60 for Peripheral T Cell Lymphoma (PTCL)
Conjupro Biotherapeutics, Inc.
Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma
Louisiana State University Health Sciences Center Shreveport
CD19-targeting CAR T Cells for B Cell Lymphoma
Fuda Cancer Hospital, Guangzhou
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
Takeda
CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma
M.D. Anderson Cancer Center
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Alliance for Clinical Trials in Oncology
Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
University of Washington
Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Ann & Robert H Lurie Children's Hospital of Chicago
A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia
Scripps Health
Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients
Kahr Medical
RELIEF
Edwards Lifesciences
ABC-102
RedHill Biopharma Limited
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
Masonic Cancer Center, University of Minnesota
Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
University of Michigan Rogel Cancer Center
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
Western Regional Medical Center
Intratumoral Dendritic Cell Vaccination Combined With Local Radiotherapy in Patients With Recurrent Lymphoma.
Baylor Research Institute